invIOs / APEIRON Biologics: Vienna Business Agency to fund R&D project in immune-oncology

invIOs GmbH, a fully owned subsidiary of APEIRON Biologics AG intends to develop a new adoptive cell therapy (ACT) for individualized treatment based on tumor-infiltrating lymphocytes (TIL) isolated from primary tumors such as glioblastoma (project INV441).

Glioblastoma multiforme (GBM), a rare and aggressive brain cancer, is mostly incurable with limited therapeutic options and a 5-year survival rate of only 5%. Nowadays, immunotherapy such as anti-PD-1/PD-L1 have become a routine treatment in many tumors. However, they failed to show survival benefits in GBM so far. Recently it was confirmed that deletion of Cbl-b, but not PD-1, restored T cell responsiveness proving invIOs’ approach of Cbl-b silencing in TILs to boost anticancer immunity. A TIL ACT process development accompanied by preclinical tests and a novel mouse model mimicking GBM will be set up. Cbl-b silenced TILs will result in enhanced antitumor activity either by reinfusion or direct delivery to the tumor, thus potentially overcoming constraints of other approaches. This ACT platform is currently being used (project APN401) in an out-patient setting utilizing Peripheral Blood Mononuclear cells (PBMC) in patients with advanced-stage solid tumors in a Phase 1b clinical trial. The platform may also be expanded to other tumor indications in adult and pediatric patients, both in solid and hematological cancers thus being of significant benefit and high commercial value.

Vienna Business Agency invested in invIOs / APEIRON Biologics

For more than 20 years, the Vienna Business Agency has been strengthening Vienna’s biotechnology, medical device and pharmaceutical sector. Today it is one of Austria’s most important facilitators for innovation. In December 2021 the Vienna Business Agency granted more than € 4.5 million to support new business R&D projects in the life sciences, after a hard and fair review process. The project proposed by invIOs / APEIRON Biologics is one of 13 high quality proposals the jury recommended for funding.

About invIOs GmbH

invIOs offers unique and highly promising new treatment options in the INNOVATIVE THERAPY area of IMMUNO-ONCOLOGY. We are pioneers in research & development of drug candidates in CELL THERAPIES targeting new immune checkpoints and in Immunomodulation.


Campus-Vienna-Biocenter 5, 1030 Vienna, Austria
Tel +43 1 86565 77

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)